Epizyme - EPZM Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EPZM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View EPZM analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month price targets for Epizyme's shares. Their EPZM share price forecasts range from $1.50 to $6.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for EPZM or view top-rated stocks among Wall Street analysts.

Epizyme's stock was trading at $2.50 at the start of the year. Since then, EPZM shares have decreased by 41.2% and is now trading at $1.47.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our EPZM earnings forecast.

Epizyme, Inc. (NASDAQ:EPZM) posted its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.15. The biopharmaceutical company earned $27.53 million during the quarter, compared to the consensus estimate of $10.11 million. Epizyme had a negative net margin of 391.90% and a negative trailing twelve-month return on equity of 2,459.33%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX).

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Shares of EPZM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EPZM stock can currently be purchased for approximately $1.47.

Epizyme (NASDAQ:EPZM) has a market capitalization of $247.44 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251,120,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

The company employs 250 workers across the globe.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at monique@thrustsc.com, or via fax at 617-349-0707.